Quercetin demonstrated consistent protective effects against pulmonary fibrosis across 24 animal studies involving 570 subjects, significantly reducing fibrotic scores and biomarkers through anti-inflammatory and antioxidant pathways. This flavonoid, abundant in onions, apples, and berries, appears to interrupt the progressive scarring that characterizes this fatal lung condition. The findings consolidate scattered evidence suggesting quercetin's therapeutic potential for a disease with limited treatment options. However, the translation from animal models to human applications faces significant hurdles. Pulmonary fibrosis affects approximately 200,000 Americans, with median survival under five years, making any protective intervention critically important. The researchers noted substantial study heterogeneity and methodological limitations that compromise confidence in the results. While quercetin's senolytic properties—its ability to clear damaged cells that drive aging—couldn't be definitively established in this lung context, the consistent anti-fibrotic signal across diverse animal models suggests biological plausibility. This represents incremental but meaningful progress in understanding quercetin's respiratory benefits, though rigorous human trials remain essential before clinical recommendations.